Eloxx Pharmaceuticals Performance
| ELOXDelisted Stock | USD 6.12 0.30 4.67% |
The firm shows a Beta (market volatility) of -1.68, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Eloxx Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Eloxx Pharmaceuticals is expected to outperform it. Eloxx Pharmaceuticals right now shows a risk of 0.0%. Please confirm Eloxx Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Eloxx Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eloxx Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Eloxx Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 42.6 M |
Eloxx |
Eloxx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 612.00 in Eloxx Pharmaceuticals on September 2, 2024 and sell it today you would earn a total of 0.00 from holding Eloxx Pharmaceuticals or generate 0.0% return on investment over 90 days. Eloxx Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Eloxx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eloxx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eloxx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Eloxx Pharmaceuticals, and traders can use it to determine the average amount a Eloxx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ELOX |
Based on monthly moving average Eloxx Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eloxx Pharmaceuticals by adding Eloxx Pharmaceuticals to a well-diversified portfolio.
Eloxx Pharmaceuticals Fundamentals Growth
Eloxx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Eloxx Pharmaceuticals, and Eloxx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eloxx Pink Sheet performance.
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 30.28 M | ||||
| Shares Outstanding | 2.75 M | ||||
| Price To Earning | (7.94) X | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (34.42 M) | ||||
| Cash And Equivalents | 30.05 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 13.38 M | ||||
| Book Value Per Share | (7.46) X | ||||
| Cash Flow From Operations | (31.84 M) | ||||
| Earnings Per Share | (12.93) X | ||||
| Total Asset | 21.12 M | ||||
| Retained Earnings | (274.39 M) | ||||
| Current Asset | 3.84 M | ||||
| Current Liabilities | 840.05 K | ||||
About Eloxx Pharmaceuticals Performance
Evaluating Eloxx Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Eloxx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eloxx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. Eloxx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.Things to note about Eloxx Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eloxx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Eloxx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eloxx Pharmaceuticals is not yet fully synchronised with the market data | |
| Eloxx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (36.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eloxx Pharmaceuticals currently holds about 30.05 M in cash with (31.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. |
- Analyzing Eloxx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eloxx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eloxx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eloxx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eloxx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eloxx Pharmaceuticals' pink sheet. These opinions can provide insight into Eloxx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |